drugset / Trial / NCT00977886

Safety and Pharmacokinetics of ELB353 in Healthy Men

NCT00977886 ↗

Phase 1 Completed 48 enrolled Biotie Therapies Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this trial is to study the safety and tolerability of repeated oral doses of ELB353, to evaluate the plasma levels of ELB353 and to study their effect on substances mediating inflammation.

Timeline

Start
2009-09
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ELBIMILAST Small molecule — Oral

Indications

No indication recorded.